Condition
Astrocytoma, IDH-Mutant, Grade 2
Total Trials
4
Recruiting
2
Active
3
Completed
1
Success Rate
100.0%+13% vs avg
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 40/100
Termination Rate
0.0%
0 terminated out of 4 trials
Success Rate
100.0%
+13.4% vs benchmark
Late-Stage Pipeline
25%
1 trials in Phase 3/4
Results Transparency
0%
0 of 1 completed with results
Key Signals
100% success
Data Visualizations
Phase Distribution
3Total
P 1 (2)
P 3 (1)
Trial Status
Recruiting2
Completed1
Active Not Recruiting1
Trial Success Rate
100.0%
Benchmark: 86.6%
Based on 1 completed trials
Clinical Trials (4)
Showing 4 of 4 trials
NCT06860594Phase 1RecruitingPrimary
Testing the Addition of an Anti-Cancer Drug, Triapine, to the Usual Radiation Therapy for Recurrent Glioblastoma or Astrocytoma
NCT03528642Phase 1Active Not RecruitingPrimary
Telaglenastat With Radiation Therapy and Temozolomide in Treating Patients With IDH-Mutated Diffuse Astrocytoma or Anaplastic Astrocytoma
NCT05303519Phase 3Recruiting
SIGMA (Safusidenib in IDH1 Mutant Glioma Maintenance)
NCT07673666Completed
GliomaAI-Astro23: MRI-Based Detection of IDH Mutant Astrocytoma (Grade 2 and 3)
Showing all 4 trials